Norway

EXACT Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

EXACT Therapeutics Raises NOK 155 Million and Lists on Oslo Stock Exchange's Merkur Market

Lead Product(s): ACT associated Chemotherapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $16.9 million Upfront Cash: Undisclosed

Deal Type: Private Placement July 14, 2020

Details:

The net proceeds from the private placement will be used for: completion of phase I study of ACT® in liver metastases, initiate planning and conduct supporting studies for multi-indication oncology basket trial, further development of ACT®-therapy ultrasound probe.

BerGenBio ASA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BERG Presents Results of Phase 1 Clinical Study in Glioblastoma at 2020 American Society of Clinical Oncology (ASCO) Meeting

Lead Product(s): Ubidecarenone Coenzyme, Q-10

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2020

Details:

The study, presented at the 2020 American Society of Clinical Oncology Annual Meeting (ASCO), highlights safety, tolerability and the impact of BPM 31510-IV influence on metabolism in patients, supporting planned Phase 2 clinical development.

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Targovax Announces Completed Enrollment in the ONCOS-102

Lead Product(s): ONCOS-102,Pembrolizumab,Cyclophosphamide

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 03, 2020

Details:

In this trial, ONCOS-102 immune activation is being tested in patients with advanced, unresectable melanoma who have had disease progression on treatment with anti-PD1 CPI.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

EXACT Therapeutics

EXACT Therapeutics Raises NOK 155 Million and Lists on Oslo Stock Exchange's Merkur Market

BerGenBio ASA

BERG Presents Results of Phase 1 Clinical Study in Glioblastoma at 2020 American Society of Clinical Oncology (ASCO) Meeting

Targovax

Targovax Announces Completed Enrollment in the ONCOS-102